Axon Enterprise, Inc $AXON Position Raised by DekaBank Deutsche Girozentrale

Key Points

• DekaBank Deutsche Girozentrale increased its stake in Axon Enterprise by 34.3% during the second quarter, resulting in a holding worth approximately $18.93 million as of its latest SEC filing.
• A total of 79.08% of Axon Enterprise stock is currently owned by institutional investors, with several hedge funds recently increasing their stakes significantly.
• Axon Enterprise reported earnings of $2.12 per share for the last quarter, surpassing analyst expectations of $1.54, alongside a revenue increase of 32.6% compared to the previous year.

DekaBank Deutsche Girozentrale raised its stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 34.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 22,812 shares of the biotechnology company's stock after buying an additional 5,826 shares during the quarter. DekaBank Deutsche Girozentrale's holdings in Axon Enterprise were worth $18,933,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in AXON. TCTC Holdings LLC increased its stake in Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 24 shares in the last quarter. Bartlett & CO. Wealth Management LLC increased its stake in Axon Enterprise by 132.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 33 shares in the last quarter. Banque Transatlantique SA purchased a new position in Axon Enterprise in the 1st quarter worth about $31,000. Catalyst Capital Advisors LLC purchased a new position in Axon Enterprise in the 1st quarter worth about $32,000. Finally, Flaharty Asset Management LLC purchased a new position in Axon Enterprise in the 1st quarter worth about $33,000. 79.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AXON has been the topic of several research analyst reports. Piper Sandler began coverage on Axon Enterprise in a research note on Tuesday, September 23rd. They set an "overweight" rating and a $893.00 target price on the stock. UBS Group reiterated a "neutral" rating and issued a $840.00 target price (up from $820.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. JMP Securities reiterated a "market outperform" rating and set a $825.00 price target on shares of Axon Enterprise in a report on Monday, September 29th. Zacks Research lowered Axon Enterprise from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 2nd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $870.00 price target on shares of Axon Enterprise in a report on Wednesday, September 24th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Axon Enterprise currently has a consensus rating of "Moderate Buy" and an average target price of $841.64.

Axon Enterprise Price Performance

Shares of AXON stock opened at $701.09 on Thursday. The stock's fifty day moving average is $734.21 and its 200-day moving average is $720.68. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The stock has a market capitalization of $55.04 billion, a PE ratio of 173.11, a PEG ratio of 27.46 and a beta of 1.41. Axon Enterprise, Inc has a 52 week low of $422.38 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.58. The company had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.Axon Enterprise's revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. Equities research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of the firm's stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total value of $75,254.00. Following the completion of the transaction, the director directly owned 1,416 shares in the company, valued at $1,065,596.64. This trade represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Joshua Isner sold 15,919 shares of Axon Enterprise stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $746.26, for a total value of $11,879,712.94. Following the transaction, the president owned 238,379 shares of the company's stock, valued at $177,892,712.54. This represents a 6.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 59,932 shares of company stock valued at $45,115,616 over the last 90 days. Insiders own 4.40% of the company's stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.